93.79
+1.41(+1.53%)
Currency In USD
| Previous Close | 92.38 |
| Open | 91.22 |
| Day High | 94.4 |
| Day Low | 91.22 |
| 52-Week High | 97.12 |
| 52-Week Low | 30.82 |
| Volume | 273,922 |
| Average Volume | 512,717 |
| Market Cap | 3.54B |
| PE | -17.47 |
| EPS | -5.37 |
| Moving Average 50 Days | 81.68 |
| Moving Average 200 Days | 60.19 |
| Change | 1.41 |
If you invested $1000 in Disc Medicine, Inc. (IRON) since IPO date, it would be worth $910.58 as of December 05, 2025 at a share price of $93.79. Whereas If you bought $1000 worth of Disc Medicine, Inc. (IRON) shares 3 years ago, it would be worth $5,517.06 as of December 05, 2025 at a share price of $93.79.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
GlobeNewswire Inc.
Nov 03, 2025 2:00 PM GMT
WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious h
Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Oct 21, 2025 4:14 AM GMT
WATERTOWN, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from s
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Oct 20, 2025 11:00 AM GMT
WATERTOWN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from s